AMSTERDAM, December 10, 2015 /PRNewswire/ --
myTomorrows (Amsterdam, the
Netherlands), announced today that it has started a
collaboration with Spectrum Pharmaceuticals, Inc. (Henderson, USA; NasdaqGS: SPPI) to provide access to its
liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute
lymphoblastic leukemia.
(Logo:
http://photos.prnewswire.com/prnh/20151016/277773LOGO )
In August 2012, the US FDA
approved the product for treatment of this rare type of leukemia.
Through myTomorrows' Internet-based platform, the product is now
also made available to patients and doctors in all other countries
of the world, except China,
Taiwan and Hong Kong, through an Early Access
Program.
"We are pleased to make Marqibo® also available to leukemia
patients outside of the United
States, in countries where the treatment did not yet receive
market approval," said Dr. Ronald
Brus MD, founder and CEO of myTomorrows. "By taking care of
the complex and time consuming process of receiving approval from
regulatory authorities and healthcare insurers for individual
patients, we aim to unburden these patients and their physicians by
fulfilling their request as quickly as possible."
Joseph Turgeon, President and COO
of Spectrum Pharmaceuticals said "We look forward to expand our
collaboration with myTomorrows to also bring this product to
doctors and patients through myTomorrows' global platform. It
provides an additional option for acute lymphoblastic leukemia
patients whose disease is unresponsive to available therapies and
underscores Spectrum's efforts to combat this terrible
disease."
About myTomorrows
myTomorrows provides access services to patients and physicians
in need of diagnostic tests and drugs in development. The
myTomorrows internet platform also offers uniform public
information about early access programs, clinical trials and
diagnostic tests to enhance data-driven decision making and enables
rational pharmacotherapy.
http://www.mytomorrows.com
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Oncology and Hematology.
Spectrum and its affiliates market five oncology drugs.
Additionally, Spectrum's pipeline includes three drugs in advanced
stages of clinical development. Spectrum's strong track record
in-licensing and acquiring differentiated drugs, expertise and
proven track record in clinical development have generated a
robust, diversified, and growing pipeline of product candidates in
advanced-stage Phase 2 and Phase 3 studies. More information
on Spectrum is available at http://www.sppirx.com.
Contact Erdem Yavuz,
+31-88-525-3888, Erdem.Yavuz@mytomorrows.com
Disclosure Notice
The information in this press release
is intended solely for the United
States.
SOURCE myTomorrows and Spectrum Pharmaceuticals, Inc.